US 12,453,708 B2
Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases
Yun Yen, Arcadia, CA (US); Jing-Ping Liou, Taipei (TW); and Chien Huang Lin, Taipei (TW)
Assigned to CALGENT BIOTECHNOLOGY CO., LTD., Taipei (TW)
Filed by CALGENT BIOTECHNOLOGY CO., LTD., Taipei (TW)
Filed on Oct. 23, 2023, as Appl. No. 18/492,627.
Application 18/492,627 is a continuation of application No. 15/776,698, granted, now 11,833,122, previously published as PCT/US2016/062568, filed on Nov. 17, 2016.
Claims priority of provisional application 62/256,516, filed on Nov. 17, 2015.
Prior Publication US 2024/0130984 A1, Apr. 25, 2024
Int. Cl. A61K 31/40 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/166 (2006.01); A61K 31/404 (2006.01); A61K 31/415 (2006.01); A61K 31/416 (2006.01); A61K 31/4184 (2006.01); A61K 31/426 (2006.01); A61K 31/437 (2006.01); A61K 31/44 (2006.01); A61K 31/4402 (2006.01); A61K 31/4406 (2006.01); A61K 31/4409 (2006.01); A61K 31/4453 (2006.01); A61K 31/47 (2006.01); A61K 31/4706 (2006.01); A61K 31/495 (2006.01); A61K 31/4965 (2006.01); A61K 31/505 (2006.01); A61K 31/519 (2006.01); A61K 31/5375 (2006.01); A61K 45/06 (2006.01); A61P 11/00 (2006.01); C07C 15/00 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/166 (2013.01) [A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 31/40 (2013.01); A61K 31/404 (2013.01); A61K 31/415 (2013.01); A61K 31/416 (2013.01); A61K 31/4184 (2013.01); A61K 31/426 (2013.01); A61K 31/437 (2013.01); A61K 31/44 (2013.01); A61K 31/4402 (2013.01); A61K 31/4406 (2013.01); A61K 31/4409 (2013.01); A61K 31/4453 (2013.01); A61K 31/47 (2013.01); A61K 31/4706 (2013.01); A61K 31/495 (2013.01); A61K 31/4965 (2013.01); A61K 31/505 (2013.01); A61K 31/519 (2013.01); A61K 31/5375 (2013.01); A61K 45/06 (2013.01); A61P 11/00 (2018.01); C07C 15/00 (2013.01); A61K 9/0019 (2013.01)] 9 Claims
 
1. A method for treatment of lung fibrosis in a subject, wherein the method comprises administering an effective amount of 4-(((3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl-)amino)methyl)-N-(pyridin-4-yl)benzamide, having the following formula

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, solvate or prodrug thereof as an active ingredient to the subject.